Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Patients with endoscopically diagnosed active duodenal ulcer disease were enrolled in a
randomized, double-blind, parallel and dose-ranging trial. They were randomly assigned into
three groups to be treated for up to four weeks and be seen at week 1, 2 and 4: three of
ilaprazole, 5, 10 mg/day, and one of Rabeprazole 10 mg/day as positive control. The primary
endpoint was the ulcer healing rate at week 4. Healing of ulcer was determined by its
resolution from active to scarring stage. Symptoms relief was evaluated as secondary end
points by using a graded score. Safety and tolerability were evaluated on basis of clinical
assessments.